Physician profile
Robert M Lystrup
NPI 1679957427
$3,804.09
in general payments reported to CMS, 2019-2025
25 companies · $2,055 in 2025
The $2,055 reported for 2025 was more than what 95% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $49.95 · 2023: $205 · 2024: $1,495 · 2025: $2,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,754.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $791.33 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $512.68 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $445.22 | 2023-2025 | |
| Amgen INC. | $372.94 | 2023-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $302.99 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $230.37 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Novo Nordisk INC | $200.92 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.52 | 2025 | Caplyta |
| Pfizer INC. | $135.01 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $96.63 | 2024 | Voquezna |
| Radius Health, INC. | $94.98 | 2025 | Tymlos |
| Astellas Pharma US INC | $70.78 | 2024 | Veozah |
| Sanofi Pasteur INC. | $61.67 | 2025 | |
| Exact Sciences Corporation | $50.65 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $49.95 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $43.94 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $27.90 | 2025 | |
| Merit Medical Systems INC | $22.23 | 2025 | Esophyx |
| Globus Medical, INC. | $21.12 | 2025 | Senza |
| Phadia US INC. | $20.46 | 2024 | Immunocap |
| Aimmune Therapeutics, INC. | $19.04 | 2024 | |
| Lundbeck LLC | $18.73 | 2025 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.74 | 2023 | Trulance, Xifaxan |
| Janssen Pharmaceuticals, INC | $16.49 | 2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $13.80 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lystrup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.